Quick Answer
C4 Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2023.
C4 Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2023 | $0.00 | -100.0% |
| 2022 | $9.20M | -14.6% |
| 2021 | $10.77M | +7.1% |
| 2020 | $10.05M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $0.00 | -100.0% | — |
| June 30, 2023 | $0.00 | -100.0% | -100.0% |
| March 31, 2023 | $8.62M | -15.4% | -6.2% |
| December 31, 2022 | $9.20M | -14.6% | +1.6% |
| September 30, 2022 | $9.05M | -14.5% | -12.7% |
| June 30, 2022 | $10.37M | -0.4% | +1.7% |
| March 31, 2022 | $10.19M | -0.4% | -5.3% |
| December 31, 2021 | $10.77M | +7.1% | +1.7% |
- C4 Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2023 period, C4 Therapeutics, Inc.’s long-term debt has declined by 100.0% (from $10.05 million to $0.00).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 22, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: